Acuta Capital Partners as of March 31, 2021
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 46 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Vistagen Therapeutics Com New | 9.4 | $26M | 12M | 2.13 | |
| Celldex Therapeutics Com New (CLDX) | 7.6 | $21M | 1.0M | 20.60 | |
| Kura Oncology (KURA) | 5.5 | $15M | 537k | 28.27 | |
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 3.6 | $9.9M | 1.1M | 9.04 | |
| Iveric Bio | 3.5 | $9.8M | 1.6M | 6.18 | |
| 89bio (ETNB) | 3.4 | $9.3M | 394k | 23.68 | |
| Bcls Acquisition Corp Com Cl A | 3.2 | $8.9M | 843k | 10.57 | |
| Sage Therapeutics (SAGE) | 3.2 | $8.9M | 119k | 74.85 | |
| Curis Com New | 3.1 | $8.7M | 768k | 11.32 | |
| Apricus Biosciences | 3.1 | $8.6M | 1.7M | 4.99 | |
| Essa Pharma Com New (EPIX) | 3.0 | $8.3M | 287k | 29.05 | |
| Aclaris Therapeutics (ACRS) | 2.9 | $8.0M | 318k | 25.20 | |
| Vincerx Pharma Com New (VINC) | 2.7 | $7.6M | 394k | 19.30 | |
| Xenon Pharmaceuticals (XENE) | 2.7 | $7.4M | 413k | 17.90 | |
| Athira Pharma (ATHA) | 2.7 | $7.4M | 400k | 18.40 | |
| Fulcrum Therapeutics (FULC) | 2.6 | $7.3M | 623k | 11.78 | |
| Arrowhead Pharmaceuticals (ARWR) | 2.6 | $7.2M | 108k | 66.31 | |
| Trillium Therapeutics Com New | 2.6 | $7.1M | 662k | 10.74 | |
| Chimerix (CMRX) | 2.5 | $6.8M | 708k | 9.64 | |
| Mersana Therapeutics (MRSN) | 2.1 | $5.8M | 358k | 16.18 | |
| Altimmune Com New (ALT) | 2.1 | $5.8M | 407k | 14.13 | |
| Syndax Pharmaceuticals (SNDX) | 2.1 | $5.7M | 255k | 22.36 | |
| Verastem | 2.0 | $5.7M | 2.3M | 2.47 | |
| Jiya Acquisition Corp Com Cl A | 2.0 | $5.5M | 563k | 9.84 | |
| Praxis Precision Medicines I | 1.8 | $5.1M | 154k | 32.76 | |
| Apellis Pharmaceuticals (APLS) | 1.8 | $4.9M | 113k | 42.91 | |
| Catalyst Biosciences Com New | 1.7 | $4.7M | 940k | 5.04 | |
| Rapt Therapeutics (RAPT) | 1.6 | $4.4M | 200k | 22.20 | |
| Health Sciences Acq Corp 2 Ord Shs | 1.6 | $4.4M | 393k | 11.19 | |
| Clearside Biomedical (CLSD) | 1.4 | $4.0M | 1.6M | 2.47 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.4 | $3.9M | 381k | 10.16 | |
| Selecta Biosciences (RNAC) | 1.3 | $3.7M | 823k | 4.52 | |
| Compass Pathways Sponsored Ads (CMPS) | 1.2 | $3.3M | 90k | 36.82 | |
| Iovance Biotherapeutics (IOVA) | 1.1 | $3.1M | 98k | 31.66 | |
| Vincerx Pharma *w Exp 12/24/202 | 0.8 | $2.1M | 520k | 4.04 | |
| Avidity Biosciences Ord (RNA) | 0.6 | $1.8M | 82k | 21.80 | |
| Stoke Therapeutics (STOK) | 0.6 | $1.7M | 45k | 38.84 | |
| Mirati Therapeutics | 0.6 | $1.5M | 9.0k | 171.33 | |
| Insmed Com Par $.01 (INSM) | 0.5 | $1.4M | 43k | 34.07 | |
| Cymabay Therapeutics | 0.5 | $1.4M | 315k | 4.54 | |
| Reata Pharmaceuticals Cl A | 0.5 | $1.4M | 14k | 99.71 | |
| 4d Molecular Therapeutics In (FDMT) | 0.3 | $868k | 20k | 43.40 | |
| Novavax Com New (NVAX) | 0.2 | $569k | 3.1k | 181.44 | |
| Pmv Pharmaceuticals (PMVP) | 0.2 | $456k | 14k | 32.91 | |
| Catalyst Pharmaceutical Partners (CPRX) | 0.1 | $360k | 78k | 4.62 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $249k | 93k | 2.67 |
